A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients
NCT ID: NCT03805191
Last Updated: 2019-04-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
900 participants
Study Classification
OBSERVATIONAL
Study Start Date
2019-01-01
Study Completion Date
2022-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a multicentre observational study to investigate the improvement in glucose fluctuation of sufficient acarbose therapy on type 2 diabetes patient with high blood glucose fluctuation
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes
NCT02605772
Type 2 Diabetes Mellitus
UNKNOWN
PHASE4
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus
NCT04889157
Diabetes Mellitus, Type 2
COMPLETED
PHASE1
Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes
NCT03159052
Type 2 Diabetes Mellitus
UNKNOWN
PHASE3
Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes
NCT05629806
Type 2 Diabetes
Blood Glucose Fluctuation
UNKNOWN
PHASE3
The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients
NCT02366351
Type 2 Diabetes Mellitus
UNKNOWN
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Acarbose competitively inhibits the a-glycosidase on the surface of epithelial cells from the duodenum and small intestine, delays the metabolism and assimilation of carbohydrates, and thus effectively decreases postprandial blood glucose(PBG) as well as the risk of hypoglycemia before the next meal.Acarbose is now used as the preferred drug for some patients with prediabetes and newly diagnosed type 2 diabetes millitus(T2DM).This study aims to investigate the glycemic excursions with different courses and glycated hemoglobin A1c(HbA1c) levels after treated three months with acarbose.To minimize gastrointestinal side effects，starting dosage of acarbose of 50 mg is given orally three times daily for 10 days(with the first bite) of each main meal. Glycemic excursions are evaluated using the mean amplitude of glycemic excursions (MAGE), the postprandial glycemic excursions (PPGE) and the largest amplitude of glycemic excursions (LAGE).Freestyle Libre flash glucose monitoring system (FGMS，Abbott Laboratories,USA) was administered in this study. According to the standard Freestyle Libre Pro operating guidelines, the FGMS is installed in all participants to monitor glucose levels of interstitial fluid for 14 consecutive days. The glucose sensor is inserted into the subcutaneous tissue of upper arm at 8:00-9:00 in the morning.Glucose concentrations at 7 preset times per day (before meals, 2-h after meals and at bedtime) were determined with VivaChek Ino Smart（VivaChek Laboratories, Inc., USA) every two weeks.Four days before using acarbose and five weeks after using acarbose, FGMS was using to monitor the continuous glucose.MAGE was calculated for each subject by taking the arithmetic mean of FGM values increased or decreased (from nadirs to peaks or vice versa) when both ascending and descending segments exceeded the value of one standard deviation (SD) of the FGM values for 24-h period.The primary endpoint of the study is the extent of change in MAGE.Secondary endpoints are changes in PPGE,LAGE and HbA1c. Gene polymorphism is detected for enrolled patient with poor acarbose effect.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Type 2 Diabetes Mellitus
Poor Glycemic Control
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
OTHER
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. All enrolled patients sign the informed consent. sign the informed consent form.
2. Clinical diagnosis of T2DM(1999 WHO).
3. No acarbose in nearly 3 months.
4. 7% \< HbA1c ≤10% .
5. PPGE \>2.2mmol/L and LAGE \>4.4mmol/L.
6. MAGE \> 3.9 mmol/L.
7. The previous therapy remain the same.
8. Contraception is needed for women of child-bearing age until 28 days after the end.
2. Clinical diagnosis of T2DM(1999 WHO).
3. No acarbose in nearly 3 months.
4. 7% \< HbA1c ≤10% .
5. PPGE \>2.2mmol/L and LAGE \>4.4mmol/L.
6. MAGE \> 3.9 mmol/L.
7. The previous therapy remain the same.
8. Contraception is needed for women of child-bearing age until 28 days after the end.
Exclusion Criteria
1. Women of childbearing potential unable or unwilling to use acceptable birth control, or women who are pregnant or breastfeeding.
2. Replacement or chronic systemic corticosteroid therapy. Cytochrome P450 3A4 enzyme inducer or inhibitor therapy.Antiviral therapy for immunodeficiency disease.
3. History of gastrointestinal disease or surgery including Roemheld Syndrome, severe hernia, intestinal obstruction, intestinal ulcer, gastroenterostomy, enterectomy, bariatric surgery or lap-band procedure.
4. Known immunocompromised status, including but not limited to, individuals who had undergone organ transplantation or acquired immunodeficiency syndrome (AIDS).
5. History of hemoglobinopathy .
6. Any subject who was currently abusing alcohol or other drugs or had done so within the last 12 months.
7. There are contraindications listed in the acarbose instructions.
8. History of acute or chronic pancreatitis, or current acute or chronic pancreatitis.
9. Type 1 diabetees mellitus.
10. History of diabetic ketoacidosis or hyperosmolar nonketosis coma in recent 1 month.
11. Patients with clinically apparent hepatobiliary disease, including but not limited to chronic active hepatitis and/or severe hepatic insufficiency. Alanine Aminotransferase(ALT) or Aspartate Aminotransferase(AST) \> 3x upper limit of normal (ULN), or serum total bilirubin (TB) \>34.2 μmol/L (\>2 mg/dL).
12. Patients with following renal disease history or renal disease related features:
1. History of unstable or rapidly progressing renal disease;
2. Patients with moderate /severe renal impairment or end-stage renal disease (eGFR\< 60 mL/min/1.73 m2);
3. Urinary albumin: creatinine ratio \>1800 mg/g;
4. Serum creatinine (Cr) ≥133 μmol/L (≥1.50 mg/dL) for male subjects; Serum Cr≥124 μmol/L (≥1.40 mg/dL) for female subjects;
5. Conditions of congenital renal glycosuria.
13. Any of the following cardiovascular diseases within 6 months of the enrollment visit:
1. Myocardial infarction;
2. Cardiac surgery or revascularization (coronary artery bypass graft/percutaneous transluminal coronary angioplasty);
3. Unstable angina;
4. Congestive heart failure New York Heart Association Class III or IV;
5. Transient ischemic attack or significant cerebrovascular disease.
14. Any subject , in the judgment of the investigator, was at risk that might affect the interpretation of efficacy or safety data or the conduct ion of the study，including laboratory and physical examination or ECG.
2. Replacement or chronic systemic corticosteroid therapy. Cytochrome P450 3A4 enzyme inducer or inhibitor therapy.Antiviral therapy for immunodeficiency disease.
3. History of gastrointestinal disease or surgery including Roemheld Syndrome, severe hernia, intestinal obstruction, intestinal ulcer, gastroenterostomy, enterectomy, bariatric surgery or lap-band procedure.
4. Known immunocompromised status, including but not limited to, individuals who had undergone organ transplantation or acquired immunodeficiency syndrome (AIDS).
5. History of hemoglobinopathy .
6. Any subject who was currently abusing alcohol or other drugs or had done so within the last 12 months.
7. There are contraindications listed in the acarbose instructions.
8. History of acute or chronic pancreatitis, or current acute or chronic pancreatitis.
9. Type 1 diabetees mellitus.
10. History of diabetic ketoacidosis or hyperosmolar nonketosis coma in recent 1 month.
11. Patients with clinically apparent hepatobiliary disease, including but not limited to chronic active hepatitis and/or severe hepatic insufficiency. Alanine Aminotransferase(ALT) or Aspartate Aminotransferase(AST) \> 3x upper limit of normal (ULN), or serum total bilirubin (TB) \>34.2 μmol/L (\>2 mg/dL).
12. Patients with following renal disease history or renal disease related features:
1. History of unstable or rapidly progressing renal disease;
2. Patients with moderate /severe renal impairment or end-stage renal disease (eGFR\< 60 mL/min/1.73 m2);
3. Urinary albumin: creatinine ratio \>1800 mg/g;
4. Serum creatinine (Cr) ≥133 μmol/L (≥1.50 mg/dL) for male subjects; Serum Cr≥124 μmol/L (≥1.40 mg/dL) for female subjects;
5. Conditions of congenital renal glycosuria.
13. Any of the following cardiovascular diseases within 6 months of the enrollment visit:
1. Myocardial infarction;
2. Cardiac surgery or revascularization (coronary artery bypass graft/percutaneous transluminal coronary angioplasty);
3. Unstable angina;
4. Congestive heart failure New York Heart Association Class III or IV;
5. Transient ischemic attack or significant cerebrovascular disease.
14. Any subject , in the judgment of the investigator, was at risk that might affect the interpretation of efficacy or safety data or the conduct ion of the study，including laboratory and physical examination or ECG.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Sponsor Role
collaborator
Qilu Hospital of Shandong University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lin Liao, MD
Role: PRINCIPAL_INVESTIGATOR
Qianfoshan Hospital
Yuping Zhou, MD
Role: PRINCIPAL_INVESTIGATOR
Weihai Municipal Hospital
Shuguang Pang, MD
Role: PRINCIPAL_INVESTIGATOR
Jinan Central Hospital
Fei Wang, MD
Role: PRINCIPAL_INVESTIGATOR
Huangdao Branch of Affiliated Hospital of Medical College,Qingdao University
Yongjun Jin, MD
Role: PRINCIPAL_INVESTIGATOR
Yantai Branch of Affiliated Binzhou Medical College
Tianying Xu, MD
Role: PRINCIPAL_INVESTIGATOR
People's hospital of Qihe county
Guangzhen Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
Liaocheng People's Hospital
Yunfeng Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
Linyi lanshan district diabetes hospital
Lin Sun, MD
Role: PRINCIPAL_INVESTIGATOR
Jining Medical University
Dadong Fei, MD
Role: PRINCIPAL_INVESTIGATOR
Zaozhuang Municipal Hospital
Guangling Xu, MD
Role: PRINCIPAL_INVESTIGATOR
Guanxian people's hospital of liaocheng city
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qilu Hospital of Shandong University
Jinan, , China
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G; 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. JAMA. 2013 Sep 4;310(9):948-59. doi: 10.1001/jama.2013.168118.
Reference Type
BACKGROUND
Poolsup N, Suksomboon N, Rattanasookchit S. Meta-analysis of the benefits of self-monitoring of blood glucose on glycemic control in type 2 diabetes patients: an update. Diabetes Technol Ther. 2009 Dec;11(12):775-84. doi: 10.1089/dia.2009.0091.
Reference Type
BACKGROUND
The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995 Aug;44(8):968-83.
Reference Type
BACKGROUND
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53.
Reference Type
BACKGROUND
Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007 Feb;30(2):263-9. doi: 10.2337/dc06-1612.
Reference Type
BACKGROUND
Maia FF, Araujo LR. Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients. Diabetes Res Clin Pract. 2007 Jan;75(1):30-4. doi: 10.1016/j.diabres.2006.05.009. Epub 2006 Jun 27.
Reference Type
BACKGROUND
Mastrototaro J. The MiniMed Continuous Glucose Monitoring System (CGMS). J Pediatr Endocrinol Metab. 1999;12 Suppl 3:751-8. No abstract available.
Reference Type
BACKGROUND
Ginsberg BH. The FDA panel advises approval of the first continuous glucose sensor. Diabetes Technol Ther. 1999 Summer;1(2):203-4. doi: 10.1089/152091599317431. No abstract available.
Reference Type
BACKGROUND
Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol. 2008 Nov;2(6):1094-100. doi: 10.1177/193229680800200618.
Reference Type
BACKGROUND
Guerci B. [Asymptomatic glycemic instability: how to measure it and which clinical applications? ]. Diabetes Metab. 2003 Apr;29(2 Pt 1):179-88. French.
Reference Type
BACKGROUND
Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005 May-Jun;19(3):178-81. doi: 10.1016/j.jdiacomp.2004.10.001.
Reference Type
BACKGROUND
Del Prato S. In search of normoglycaemia in diabetes: controlling postprandial glucose. Int J Obes Relat Metab Disord. 2002 Sep;26 Suppl 3:S9-17. doi: 10.1038/sj.ijo.0802172.
Reference Type
BACKGROUND
Yang W, Liu J, Shan Z, Tian H, Zhou Z, Ji Q, Weng J, Jia W, Lu J, Liu J, Xu Y, Yang Z, Chen W. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2014 Jan;2(1):46-55. doi: 10.1016/S2213-8587(13)70021-4. Epub 2013 Oct 18.
Reference Type
BACKGROUND
Li S, Xiao J, Ji L, Weng J, Jia W, Lu J, Zhou Z, Guo X, Liu J, Shan Z, Zhu D, Chen L, Zhao Z, Tian H, Ji Q, Ge J, Li Q, Lin L, Yang Z, He J, Yang W; China National Diabetes and Metabolic Disorders Study Investigators. BMI and waist circumference are associated with impaired glucose metabolism and type 2 diabetes in normal weight Chinese adults. J Diabetes Complications. 2014 Jul-Aug;28(4):470-6. doi: 10.1016/j.jdiacomp.2014.03.015. Epub 2014 Apr 1.
Reference Type
BACKGROUND
Ma RC. Acarbose: an alternative to metformin for first-line treatment in type 2 diabetes? Lancet Diabetes Endocrinol. 2014 Jan;2(1):6-7. doi: 10.1016/S2213-8587(13)70107-4. Epub 2013 Oct 18. No abstract available.
Reference Type
BACKGROUND
Chen M, Dou J, Zhuang X, Dong L, Ruan D, Ding J, Zhang Y, Tian Y, Zhao J, Wu J, Fu Y, Huang X, Wang S, Lu J. [An analysis of hypoglycemic agents used among patients with type 2 diabetes in Beijing communities]. Zhonghua Nei Ke Za Zhi. 2014 Feb;53(2):112-5. Chinese.
Reference Type
BACKGROUND
Ju-Ming L, Xiao-Hui G, Xiao-Feng L, Yan-Bing L, Li Y, Yao-Ming X. Effects of Nateglinide on Postprandial Plasma Glucose Excursion and Metabolism of Lipids in Chinese Patients with Type 2 Diabetes：A 4-week, randomized, active-control, open-label, parallel-group, multicenter trial. Curr Med Res Opin. 2012 Jul 19. doi: 10.1185/03007995.2012.713340. Online ahead of print.
Reference Type
BACKGROUND
Zhou J, Li H, Zhang X, Peng Y, Mo Y, Bao Y, Jia W. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes. Diabetes Technol Ther. 2013 Jun;15(6):481-8. doi: 10.1089/dia.2013.0046. Epub 2013 Apr 30.
Reference Type
BACKGROUND
Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10.
Reference Type
BACKGROUND
Lin SD, Wang JS, Hsu SR, Sheu WH, Tu ST, Lee IT, Su SL, Lin SY, Wang SY, Hsieh MC. The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. J Diabetes Complications. 2011 Sep-Oct;25(5):332-8. doi: 10.1016/j.jdiacomp.2011.06.004. Epub 2011 Aug 2.
Reference Type
BACKGROUND
Nomoto H, Miyoshi H, Sugawara H, Ono K, Yanagiya S, Oita M, Nakamura A, Atsumi T. A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin. Diabetol Metab Syndr. 2017 Jul 17;9:54. doi: 10.1186/s13098-017-0255-8. eCollection 2017.
Reference Type
BACKGROUND
Makdissi A, Chaudhuri A, Kuhadiya N, Batra M, Dandona P. Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes Care. 2013 Jun;36(6):e80. doi: 10.2337/dc12-2220. No abstract available.
Reference Type
BACKGROUND
Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, Farrell K, Rothenberg P, Henry RR. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013 Aug;36(8):2154-61. doi: 10.2337/dc12-2391. Epub 2013 Feb 14.
Reference Type
BACKGROUND
Deshmukh AB, Patel MC, Mishra B. SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus. Ren Fail. 2013;35(4):566-72. doi: 10.3109/0886022X.2013.766560. Epub 2013 Feb 25.
Reference Type
BACKGROUND
Wu H, Liu J, Lou Q, Liu J, Shen L, Zhang M, Lv X, Gu M, Guo X. Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus. Medicine (Baltimore). 2017 Sep;96(35):e7533. doi: 10.1097/MD.0000000000007533.
Reference Type
BACKGROUND
Wang JS, Lee IT, Lee WJ, Lin SD, Su SL, Tu ST, Tseng YH, Lin SY, Sheu WH. Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy. J Diabetes. 2017 Mar;9(3):248-255. doi: 10.1111/1753-0407.12406. Epub 2016 May 31.
Reference Type
BACKGROUND
Park S, Choi SB. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev. 2003 Mar-Apr;19(2):124-30. doi: 10.1002/dmrr.343.
Reference Type
BACKGROUND
Naqvi S, Naveed S, Ali Z, Ahmad SM, Asadullah Khan R, Raj H, Shariff S, Rupareliya C, Zahra F, Khan S. Correlation between Glycated Hemoglobin and Triglyceride Level in Type 2 Diabetes Mellitus. Cureus. 2017 Jun 13;9(6):e1347. doi: 10.7759/cureus.1347.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RD-OI-1257
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects
NCT03061981
COMPLETED
PHASE1
A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In T2DM
NCT01523405
COMPLETED
A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients
NCT03006159
COMPLETED
PHASE1
MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).
NCT00754130
COMPLETED
PHASE1
Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
NCT00763022
COMPLETED
PHASE3
A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
NCT04885712
COMPLETED
PHASE3
A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients
NCT01396161
COMPLETED
PHASE1
Study of Metformin and S. Baicalensis Combination Therapy in Type 2 Diabetes Mellitus Patients
NCT02844803
UNKNOWN
EARLY_PHASE1
A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes
NCT07122102
NOT_YET_RECRUITING
NA
Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus
NCT00532506
COMPLETED
PHASE2
A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes
NCT03315780
COMPLETED
PHASE4
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
NCT00086515
COMPLETED
PHASE3
Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy
NCT00568035
COMPLETED
PHASE2
Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes
NCT01758471
UNKNOWN
PHASE4
Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)
NCT01545388
COMPLETED
PHASE3
A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM
NCT03646721
COMPLETED
PHASE1
The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus Patients
NCT02366377
UNKNOWN
PHASE1
Special Drug Use Investigation of Glucobay OD
NCT01685502
COMPLETED
Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin
NCT03851432
UNKNOWN
PHASE3
A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes
NCT00857558
COMPLETED
PHASE2
Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects
NCT01156779
COMPLETED
PHASE1
Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.
NCT00759720
TERMINATED
PHASE3
Randomized, Double-blind Study to Assess the Efficacy and Safety of α-lipoic Acid Versus BK-C-0701 in Subjects With Diabetic Neuropathy
NCT01261143
COMPLETED
PHASE3
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
NCT07244003
RECRUITING
PHASE4
The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
NCT05029115
ENROLLING_BY_INVITATION